BioReliance® Introduces Advanced In Vitro ADME and Toxicology Services Designed to Improve Drug Safety and Efficacy BioReliance® (www.bioreliance.com), Sigma-Aldrich Corporation’s (NASDAQ: SIAL) biologics and early-development services business under SAFC® Commercial
Merck to Acquire Sigma-Aldrich to Enhance Position in Attractive Life Science Industry Merck to acquire Sigma-Aldrich for $140 per share in cash, valuing company at approx. $17 billion (€13.1 billion)
Lonza Half-Year Business Performance Fully on Track Business is fully on track with a CORE EBIT growth of 13.1% compared with the first half of 2013 despite currency headwinds Revenue